Functional and Ultrasound Guided Resection of Glioblastoma

Glioma Glioblastoma Multiforme Clinical Trial

— FUTURE-GB  

Official title:

FUTURE-GB Trial (Functional and Ultrasound-guided Resection of Glioblastoma) A 2-Stage Trial. A Learning Phase Evaluation of Participating Centres, Followed by a Randomised, Controlled Multicentre Phase III Trial.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05399524
• Other study ID #: 14763
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2020
• Est. completion date: November 2025

Study information

• Verified date: April 2022
• Source: University of Oxford
• Contact: Amy Taylor
• Phone: 44 7917 101 649
• Email: futuregb[@]nds.ox.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours

Description:

Stage 1 (IDEAL IIB study) of the trial is observational only and all participants will receive all technologies during surgery.

Stage 2 will be randomised. Randomisation will be via the web-based service provided by the Oxford Clinical Trials Research Unit (OCTRU), using the method of minimisation. Participants will be randomised 1:1 to either:

1. Standard care surgery (neuronavigation based on preoperative imaging and intraoperative use of 5-ALA)(Control arm)

2. Standard care surgery (neuronavigation based on preoperative imaging and intraoperative use of 5-ALA) AND of DTI neuronavigation and NiUS (Intervention arm)

At baseline all participants will undergo a routine preoperative neuronavigation MRI scan. Those participants randomised to the experimental arm, will also have a DTI scan (additional 5 minutes in the MRI). All participants will then undergo the planned resection of their tumour, with the additional technologies if they are in the experimental arm. Following surgery, participants in both arms have the same follow up schedule and undergo standard clinical care for a total of 24 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 357
• Est. completion date: November 2025
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age 18-70 years

• Neuro-oncology Multi-Disciplinary Team (MDT) decision that the imaging shows a primary GB tumour which is maximally resectable (attempted gross total resection of all enhancing tumour)

• Patient is suitable for concomitant adjuvant radiotherapy and Temozolomide (TMZ) chemotherapy or adjuvant TMZ at the time of MDT decision

• Able to receive 5-ALA

• Willing and able to give informed consent

• Able to complete trial questionnaires, this may be with support where English is not their first language. (Stage 2 only)

• Able to provide a proxy who is willing to complete questionnaires as requested (Stage 2 only).

Exclusion Criteria:

• Midline/basal ganglia/cerebellum/brainstem GB

• Multifocal GB

• Recurrent GB

• Suspected secondary GB

• Contraindication to MRI

Related Conditions & MeSH terms

• Glioblastoma
• Glioma Glioblastoma Multiforme

Intervention

Other:
• Standard of Care
Neuronavigation and intraoperative 5-ALA
• Additional pre- and intra-operative imaging
Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)

Locations

Country	Name	City	State
United Kingdom	Queen Elizabeth Hospital, University Hospitals Birmingham NHSFT	Birmingham
United Kingdom	Royal Sussex County Hospital	Brighton
United Kingdom	Southmead Hospital, North Bristol NHST	Bristol
United Kingdom	Addenbrookes Hospital, Cambridge University NHSFT	Cambridge
United Kingdom	University Hospital of Wales, Cardiff & Vale University Health Board	Cardiff
United Kingdom	University Hospital, Coventry	Coventry
United Kingdom	Ninewells Hospital, NHS Tayside	Dundee
United Kingdom	The Royal Infirmary of Edinburgh, NHS Lothian	Edinburgh
United Kingdom	Hull Royal Infirmary	Hull
United Kingdom	Leeds General Infirmary	Leeds
United Kingdom	The Walton Centre	Liverpool
United Kingdom	Charing Cross Hospital/St Mary's, Imperial College Healthcare NHS Trust	London
United Kingdom	King's College Hospital	London
United Kingdom	Royal London Hospital, Barts Health NHS Trust	London
United Kingdom	James Cook University Hospital, South Tees Hospitals NHSFT	Middlesbrough
United Kingdom	Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHSFT	Newcastle Upon Tyne
United Kingdom	Queen's Medical Centre, Nottingham University Hospitals NHST	Nottingham
United Kingdom	The John Radcliffe Hospital, Oxford University Hospitals NHSFT	Oxford
United Kingdom	Derriford Hospital, University Hospitals Plymouth NHS Trust	Plymouth
United Kingdom	Royal Preston Hospital, Lancashire Teaching Hospitals NHSFT	Preston
United Kingdom	Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHST	Romford
United Kingdom	Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust	Sheffield
United Kingdom	Southampton General Hospital, University Hospital Southampton NHSFT	Southampton
United Kingdom	Royal Stoke University Hospital, University Hospitals of North Midlands NHST	Stoke-on-Trent

Sponsors (3)

Lead Sponsor	Collaborator
University of Oxford	Efficacy and Mechanism Evaluation (EME) Programme, Imperial College Healthcare NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Tertiary Mechanistic Objectives (on a sub set of participants): assessment of the sensitivity and specificity of the anatomico-spatial location of DTI fibre tracts compared to Standard of Care	To assess the sensitivity and specificity of the anatomico-spatial location of DTI fibre tracts compared with intraoperative direct electrical stimulation/behavioural change without stimulation but related to adjacent white fibre tract in patients undergoing awake surgery, or motor evoked potential changes in patients undergoing surgery.; Measured by sensitivity and specificity calculation using pre and post-surgery MRI images	6 weeks post-surgery
Other	Tertiary Mechanistic Objectives (on a sub set of participants): assessment of the sensitivity and specificity of iUS to identify the tumour boundary when compared with 5-ALA.	To assess the sensitivity and specificity of iUS* to identify the tumour boundary when compared with 5-ALA, navigated biopsies will be taken from tumour boundary tissue planned for resection.; Intra operative iUS* images and post-operative MRI scans and Intraoperative biopsy samples	6 weeks post-surgery
Primary	Stage 1 Primary Outcome: to demonstrate the feasibility of using DTI and iUS in addition to standard of care for neurosurgery using a combination of qualitative and quantitative data to prove workflow capability at each site.	Sites are qualitatively assessed through a standardisation stage, providing feedback to enable learning and ensure the workflow is followed. Sites with satisfactory data will "progress" and pass into Stage 2.; The measures assessed in combination are: Operation length, in normal range for this surgery.; Use of DTI neuronavigation & iUS to achieve maximal safe tumour resection without major neurological deficit, measured by getting clear, relevant images for the DTI & US scans, and accurate pre-operative tractography.; Extent of tumour resection (cm³ remaining) on postoperative MRI scan.; Surgical Complications/Serious Adverse Events-measured from recorded post-operative complications and a 6-month notes check to ensure patient safety.; If the assessment panel is satisfied with the data after ~3 recruits, a site will progress into Stage 2 of the trial, the RCT. Data will be analysed for Stage 1 once all sites have progressed through into Stage 2 of the trial.	Measured 6 weeks post-surgery
Primary	Stage 2 Primary Outcome: to assess whether additional imaging to standard of care changes Deterioration Free Survival (DFS) (Where deterioration relates to global health status only)	This is measured by a composite of: Change in global health status domain of the QLQ-C30 questionnaire (Quality of Life Questionnaire Cancer) from baseline to final questionnaire completion. Questionnaires are administered at baseline, 6 weeks, then every 3 months until 24months.; Progression Free Survival (PFS). This is measured by radiological tumour progression on imaging, which is taken 3-months post-op and 3-monthly thereafter.; Overall Survival (OS) with an event defined as either deterioration, progression or death.	Measured from baseline up to 24 months
Secondary	Stage 2: To assess if additional intraoperative imaging changes DFS where deterioration relates to physical and social functioning, and motor and communication dysfunction	This is measured using a combination of specific questions (physical functioning and social functioning) in the QLQ-C30 (Quality of Life Questionnaire Cancer) and BN20 questionnaire (Quality of Life Questionnaire Brain) (motor dysfunction and communication deficit questions), combined with the values of Progression Free Survival (PFS) and overall survival (OS) taken from the primary outcome.; Questionnaires are administered at baseline, 6 weeks, then every 3 months until 24months.	Measured from baseline up to 24 months
Secondary	Stage 2: To assess whether additional intraoperative imaging to standard of care changes time to deterioration	Defined similar to DFS with the exception that progression is excluded as an event (i.e. only deterioration or death are considered). There will be five time to deterioration outcomes, one for each of the domains utilised in the primary and secondary DFS outcomes, used in turn to define deterioration	Measured from baseline up to 24 months
Secondary	Stage 2: To assess whether additional intraoperative imaging to standard of care improves Overall Survival (OS)	OS (time from randomisation to death or trial closure)	To be recorded at 24 months
Secondary	Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes Progression Free Survival (PFS)	PFS (time from randomisation to radiological tumour progression on imaging, as agreed in local MDT; This involves using the post-operative MRI scan as a reference point and making comparisons will the ensuing MRI reports that are recieved 3 months post-surgery and 3 monthly thereafter until 24 months post-surgery.	MRI at 6 months post-op., and then 3 monthly up to 24 months or an MRI performed outside protocol if patient is symptomatic
Secondary	Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the extent of tumour resection	Extent of resection as percent of pre-operative tumour volume on postoperative contrast enhanced MRI	Measured 1 week post-surgery
Secondary	Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the incidence of surgical complications	Number and type of surgical complications	Measured from surgery up to 24 months
Secondary	Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the number of patients eligible for adjuvant treatment following surgery	Number of patients eligible for adjuvant treatment	Measured 3 months post surgery
Secondary	Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes functional outcome postoperatively	Measured by any change in the functional performance assessment which consistes of a combination of: The WHO (World Health Organisation) performance status; A 5-minute telephone mini-MoCA (The Montreal Cognitive Assessment, Montreal Version); Barthel Index; MRC (Medical Research Council) grading of power in all 4 limbs; Assessments are made at baseline, at hospital discharge, 6 weeks post-op, 3 months post-op, then 3 monthly thereafter until 24 months.	Measured from baseline up to 24 months
Secondary	Stage 2: Assess the correlation of proxy to participant classification assessment of quality of life	Assessed using comparisons between the patient and proxy responses to the Quality of Life questionnaires administered. Specifically comparisons between the answers to questions 29 and 30 of the QLQ-C30.	Measured from baseline up to 24 months. Proxy will not complete questionnaires when participant stops completing them.